-
Aug.142018NEWS
HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion
HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaroun..
-
Jul.112018NEWS
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch..
-
Jun.252018NEWS
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization(WHO)
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World He..
-
May.292018NEWS
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036(a new drug for dry eye syndrome) in the U.S.
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036..
-
May.292018NEWS
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036(a new drug for dry eye syndrome) in the U.S.
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036..
-
May.242018NEWS
IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American Society of Clinical Oncology
IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American ..